Pending acquisition: Merck KGaA is acquiring Silence for $20.00 per ADS in cash, expected to close in Q1 2027.
What they do
We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
47.2M
Pre-funded warrants
0.0M
Options
1.9M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
49.2M
Cap table as of 2026-06-30.
Merck KGaA, Darmstadt, Germany announced on October 19, 2026 that it will acquire Silence for $20.00 per ADS in cash (each ADS representing three ordinary shares), approximately $1.3 billion in equity value, by a UK scheme of arrangement expected to close in the first quarter of 2027, subject to Silence shareholder approval, High Court sanction and regulatory approvals. The share counts and cash on this page are Silence standalone and stay accurate until the deal closes; after closing the stock will be delisted.
Status note Described as Phase 3-ready; no Phase 3 initiated per filing, so stage is kept at Phase 2.
SLN312
Phase 1 · ActiveModality: siRNA
Aliases AZD1705
Target ANGPTL3
Partnerships AstraZeneca (collaboration; AZ will not pursue beyond Phase 1, Silence regains full global rights)
Indications
dyslipidemia(Phase 1)
Status note Phase 1 results presented May 2026; Silence evaluating plans for further clinical development; no discontinuation disclosed.
SLN365
Preclinical · ActiveModality: siRNA
Target GPR146
Indications
hypercholesterolemia(Preclinical)
Catalysts
— 2027
Status note Preclinical; well positioned for a potential IND filing in 2027.
SLN098
Preclinical · ActiveModality: siRNA
Target INHBE
Indications
obesity(Preclinical)
Status note Preclinical.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.